Aussie Scientists ID Gene That Blocks Main Hepatitis C Drugs In Many
This article was originally published in PharmAsia News
Executive SummaryAustralian researchers say they have identified the gene responsible for the lack of the ability of half of Australians infected with hepatitis C to respond to conventional treatment. The Westmead Millenium Institute scientists said the interferon lambda gene has the ability to block the effectiveness of drugs used to treat the chronic infection of liver diseases. About 200,000 Australians have hepatitis C, half of whom fail to respond to the usual treatments. (Click here for more
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.